Viromed Medical

What Viromed Medical does

Viromed Medical AG is a publicly listed German medical technology company (Frankfurt Stock Exchange, ticker VMED) that develops, manufactures, and distributes medical devices based on cold atmospheric plasma (CAP/KAP) technology. Founded in 2004 as a research entity and listed in October 2022, the company holds cold plasma IP through its majority stake in terraplasma medical GmbH, which originated from the Max Planck Institute. Its portfolio centers on the ViroCAP family of portable, MDR-2a-certified handheld plasma devices for skin and wound infections across human medicine, dermatology, podiatry, veterinary, and cosmetic applications, the PulmoPlas stationary system under development for prevention and treatment of ventilator-associated pneumonia (VAP), and room air decontamination devices (KLINIK AKUT V 500 Plasma, Virosafe 2500). The technology inactivates viruses, bacteria including multi-resistant pathogens such as MRSA, fungi, and spores, while stimulating tissue healing; clinical studies report up to 80% wound size reduction within 30 days, up to 52% reduction in chronic wound treatment costs, and 100% MRSA kill rates in vitro within 30-90 seconds on human lung cells without damaging respiratory epithelia.

Viromed generates revenue primarily through hardware sales of its proprietary devices, OEM production for white-label partners, licensing/license fees, and government research grants. The company sells directly to healthcare institutions in the DACH region (where it positions as central supplier to 650 acute clinics, 1,100 hospitals, 2,000 nursing homes, and 12,000 medical practices) and reaches international markets through exclusive distribution partners covering Asia (UMECO Group, EUR 152.5M, 5-year commitment), Turkey (Tripart Titan), European podiatry (HELLMUT RUCK GmbH, 120,000+ customers), DACH and global veterinary (AMAMUS Vet, NEBU-TEC), and European cosmetics (Landsberg First Class Aesthetic). FY2025 consolidated revenue reached EUR 5.1M (up from EUR 1.1M in FY2024) and the company achieved a positive net result of EUR 0.6M, marking its transition from a research-intensive pre-revenue entity to an early commercial-stage medical device business.

The business model is asset-light in distribution: Viromed relies heavily on exclusive partner channels and OEM arrangements to access fragmented healthcare end-markets rather than building a global direct sales force. Customer segments span human medicine, veterinary, podiatry, cosmetics, and intensive care pulmonology, with research validation from Hannover Medical School, Helmholtz Centre for Infection Research, and University Medical Center of the Saarland. The company has pursued an inorganic growth strategy, acquiring Pharmedix GmbH in December 2024 and signing a letter of intent to acquire relyon plasma GmbH in March 2026 to consolidate cold plasma technology capabilities, while securing grant funding from the German Federal Ministry of Research, Technology and Space (BMBF) under the Research Allowance Act to advance PulmoPlas regulatory approval.

Name

Viromed Medical

Legal name

Viromed Medical AG

Website

https://viromed.de

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Viromed Medical AG is a German publicly listed medical technology company that develops and distributes cold atmospheric plasma devices (ViroCAP family and PulmoPlas) for wound care, dermatology, veterinary, cosmetics, and ventilator-associated pneumonia treatment, selling via exclusive distribution partners and direct channels to hospitals, clinics, and practices across DACH, Asia, and Europe.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Industrial and Commercial Fan and Blower and Air Purification Equipment Manufacturing (333413), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Industrial & Commercial Fans & Blowers & Air Purifing Equip (3564), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Air Quality & Environmental Infection Control (HEPA Filtration, Isolation Barriers, CSSD/HVAC Solutions) (HLAHANAK)

akta.pro secondary industry

Sterilization Equipment & Systems (Autoclaves, Low-Temp, ETO, H2O2, UV) (HLAHANAA)

Keywords

• Cold plasma medical devices
• Wound care technology
• Air decontamination systems
• Infection control devices
• Ventilator pneumonia treatment

Headquarters

HQ city

Pinneberg

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical device sales (ViroCAP): Sale of ViroCAP cold plasma medical devices across multiple variants (medical, dermatology, podology, veterinary, cosmetic). Revenue generated from direct sales and through distribution and OEM partners. Sales started Q4 2025. Revenue grew from €1.1M (2024) to €5.1M (2025).
2. Licensing fees and purchase commitments (UMECO Group): One-time license fee of USD 5 million received upon signing with UMECO Group (April 2025), plus purchase commitments of EUR 32.5M in 2026 and EUR 60M each in 2027 and 2028 (total EUR 152.5M over 5 years across 10 Asian countries for ViroCAP and PulmoPlas).
3. OEM production revenue: Production of OEM versions of ViroCAP for partners such as HELLMUT RUCK GmbH, generating revenue through device sales under partner branding.
4. Veterinary device distribution: Revenue from sale of ViroCAP vet through exclusive distributors (AMAMUS Vet, NEBU-TEC) with minimum purchase volumes (e.g., 1,000 devices over 12 months for AMAMUS Vet DACH).
5. Cosmetics device and consumables (Landsberg): Revenue from sale of ViroCAP my Plasma through Landsberg First Class Aesthetic for cosmetic/aesthetic applications in Europe, with long-term revenue through associated spacer sales (target: 5,000 devices over 3 years).
6. Government research funding: Funding from the German Federal Ministry for Research, Technology and Space (BMBF) under the Research Allowance Act (FZulG), comprising a high six-figure euro amount for R&D in cold plasma technology.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels6 records

Core offering

Viromed Medical manufactures and distributes cold atmospheric plasma (CAP) medical devices. Its flagship ViroCAP product line consists of portable, handheld, battery-operated medical devices for treating skin and wound infections, dermatological conditions, and veterinary applications, certified as MDR Class IIa. Its PulmoPlas system is a stationary cold plasma device designed for integration into mechanical ventilation processes to prevent and treat ventilator-associated pneumonia. The company also produces room air decontamination devices (KLINIK AKUT V 500 Plasma, Virosafe 2500) for clinical air sterilization.

Product overview

Viromed Medical's product portfolio centers on cold atmospheric plasma (KAP/CAP) medical technology across a suite of targeted product lines. The core offering consists of the ViroCAP® family — portable plasma devices for skin, wound, and dermatological applications — available in variants for human medicine (ViroCAP® med, ViroCAP® derma), podiatry (ViroCAP® Podologie/OEM for HELLMUT RUCK), veterinary medicine (ViroCAP® vet via AMAMUS Vet), and cosmetics (ViroCAP® My Plasma via Landsberg). The second flagship product, PulmoPlas®, is a stationary plasma system integrated into mechanical ventilation for treating and preventing ventilator-associated pneumonia (VAP). Supporting the portfolio are room air decontamination devices (KLINIK AKUT V 500 Plasma, Virosafe 2500). The company operates with a platform approach, distributing via wholly owned subsidiary Viromed Medical GmbH, and extends reach internationally through partnerships including NEBU-TEC (veterinary PulmoPlas®), UMECO Group (Asia), Tripart Titan (Turkey), and AMAMUS Vet (DACH veterinary).

Differentiator

Problem solved

Functional benefit

Brands

• ViroCAP: Mobile medical cold plasma device for treatment of skin and wound infections, dermatology applications. Includes ViroCAP med (human medicine), ViroCAP derma (dermatology), ViroCAP vet (veterinary), and ViroCAP My Plasma (cosmetics/aesthetic). Certified as MDR Class IIa medical device.
• PulmoPlas
• plasma care
• KLINIK AKUT V 500 Plasma
• Virosafe 2500

Products and services

• ViroCAP med A portable, MDR Class IIa-certified cold plasma medical device for treating skin and wound infections, dermatological applications, and inactivation of viruses, bacteria, multi-resistant pathogens, and fungi on skin tissue. Handheld and battery-operated, weighing 350g, with piezoelectric plasma generator.
• ViroCAP derma A cold plasma dermatology device variant for treating skin diseases and dermatological conditions using cold atmospheric plasma.
• ViroCAP vet A cold plasma medical device variant for veterinary use, exclusively distributed via AMAMUS Vet for treatment of skin infections, eczema, allergic skin reactions, and bite wounds in animals.
• ViroCAP My Plasma ViroCAP branded for cosmetic and aesthetic applications, distributed exclusively by Landsberg First Class Aesthetic in Europe, targeting aesthetic doctors, spa managers, therapists, and high-class aesthetic institutes.
• ViroCAP Podologie (OEM for HELLMUT RUCK) ViroCAP variant tailored for podiatry applications, marketed exclusively in Europe, the United Kingdom, and Switzerland through HELLMUT RUCK GmbH, providing access to over 120,000 podiatry customers via the RUCK distribution network and RUCK Akademie.
• PulmoPlas A stationary cold plasma medical device designed for integration into mechanical ventilation processes for the prevention and treatment of ventilator-associated pneumonia (VAP) in mechanically ventilated ICU patients, using cold atmospheric plasma to selectively inactivate pathogenic germs in the lower respiratory tract. Demonstrated 100% efficacy against MRSA in vitro in 30-90 seconds. Undergoing MDR approval process with BfArM application filed.
• KLINIK AKUT V 500 Plasma A room air decontamination device (Entkeimung) utilizing cold plasma technology for air sterilization in acute clinical and hospital settings.
• Virosafe 2500 A room air decontamination device employing cold plasma technology for air sterilization, positioned within the room air purification product lineup.

Quantifiable outcome

• ViroCAP reduces wound size by ~80% in under 30 days with only 7 treatment sessions
• +7 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, minor and flagship.

• NEBU-TEC International med. Produkte Eike Kern GmbHcoreChannel Partner/ Reseller/ Distributor · 18 May 2026Worldwide exclusive distribution partnership for PulmoPlas in veterinary applications. Combines Viromed's cold plasma technology with NEBU-TEC's nebulization/inhalation technology. First focus on equine lung diseases. NEBU-TEC's Class IIa MDR devices enable future human medicine applications with PulmoPlas med. Sales start planned for 2026.
• HELLMUT RUCK GmbHcoreOEM/ Whitelabel/ Licensing Partner · 21 April 2026OEM production partnership for ViroCAP in podiatry. Viromed produces OEM versions of ViroCAP per RUCK's design specifications for exclusive distribution in podology across Europe, UK, and Switzerland. RUCK has 120,000+ podiatry customers and operates the RUCK Akademie for professional training. Production started April 2026. Further international sales cooperations in preparation.
• relyon plasma GmbHcoreStrategic or Co-development Partner · 4 March 2026Viromed signed a letter of intent to acquire relyon plasma GmbH as a strategic step toward an integrated cold plasma technology platform. Due diligence processes underway. relyon plasma GmbH collaborated with Viromed on technical optimization of ViroCAP, which was successfully completed.
• Hannover Medical School (MHH)coreStrategic or Co-development Partner · 30 September 2025Research collaboration for in vivo and ex vivo studies with cold plasma on living lungs for treating ventilator-associated pneumonia. Led by Prof. Hortense Slevogt (MHH and Helmholtz Centre for Infection Research). Demonstrated 100% MRSA efficacy in vitro with human alveoli cells. Ongoing clinical studies; results for VAP prevention study expected 2026.
• University Medical Center of the SaarlandminorStrategic or Co-development Partner · 29 July 2025Research partner in the comprehensive scientific development programs for PulmoPlas pulmonary cold plasma applications, alongside Hannover Medical School and Helmholtz Centre for Infection Research.
• EWMA (European Wound Management Association)minorStrategic or Co-development Partner · 29 July 2025Viromed is a member of the EWMA Innovation Alliance. Participated at EWMA 2026 congress for international market launch of ViroCAP.
• Tripart Titan GmbH & Co KGcoreChannel Partner/ Reseller/ Distributor · 24 July 2025Exclusive distribution partnership for ViroCAP and PulmoPlas in Turkey for both human medicine and veterinary applications. Announced July 2025.
• Landsberg First Class AestheticcoreChannel Partner/ Reseller/ Distributor · 25 April 2025Exclusive distribution of ViroCAP my Plasma for cosmetic and aesthetic applications in Europe. Target of 5,000 devices over 3 years with long-term revenue from associated spacer consumables. Landsberg serves aesthetic doctors, 5-star hotels, and high-class aesthetic institutes with ~7,500 B2B customers globally.
• AMAMUS Vet / Lang Life Sciences GmbHcoreChannel Partner/ Reseller/ Distributor · 10 April 2025Exclusive distribution partnership for ViroCAP VET in DACH region (Germany, Austria, Switzerland) for veterinary dermatological treatments (skin infections, eczema, allergic reactions, bite wounds). Minimum 1,000 devices in first 12 months. Distribution under AMAMUS Vet brand with deliveries starting August 2025.
• UMECO GroupflagshipChannel Partner/ Reseller/ Distributor · 1 April 2025Exclusive 5-year distribution agreement worth EUR 152.5 million covering 10 Asian countries (Korea, Taiwan, Thailand, Indonesia, Japan, Shanghai, Philippines, Singapore, Malaysia, Vietnam). Viromed receives USD 5M license fee plus purchase commitments of EUR 32.5M (2026) and EUR 60M each (2027, 2028). Covers ViroCAP and PulmoPlas for dermatological and pneumological treatments in medical and cosmetic use.
• Helmholtz Centre for Infection Research (HZI)coreStrategic or Co-development Partner · 14 March 2025Collaborative research with Hannover Medical School on cold plasma safety and efficacy for treating VAP in mechanically ventilated patients. Prof. Hortense Slevogt leads the study combining both institutions. Research focused on killing antibiotic-resistant bacteria (MRSA) in the respiratory tract without damaging lung tissue.
• Pharmedix GmbHminorOthers · 20 December 2024Viromed Medical AG completed acquisition of Pharmedix GmbH in December 2024, expanding its portfolio and market presence.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

Emerging players

• Camfil AB: Global air filtration and clean air solutions provider serving hospitals, life sciences, and commercial buildings with HEPA and molecular filtration. Adjacent to Viromed's room air decontamination line; differentiated by mechanical filtration rather than cold plasma technology.

Direct peers

• IQAir: Swiss-based manufacturer of high-performance air purifiers and indoor air quality solutions used in healthcare, schools, and commercial settings. Comparable to Viromed's Virosafe and KLINIK AKUT room air decontamination devices, with overlapping healthcare customer base.
• Hamilton Medical: Swiss manufacturer of mechanical ventilators and ICU respiratory solutions, with deep installed base in the exact ICU/ventilated-patient setting where PulmoPlas aims to prevent VAP. Direct adjacency for the PulmoPlas use case as a complementary technology to Hamilton's ventilation hardware.
• Mölnlycke Health Care: Global wound care and surgical solutions company whose core business centers on advanced wound management (e.g. Mepilex, Mepitel). Directly comparable to Viromed's ViroCAP/plasma care franchise, which targets chronic and acute wound healing as a non-pharmacological alternative in the same hospital customers.
• ConvaTec Group plc: Global medical products company with an Advanced Wound Care franchise serving hospitals and homecare. Comparable on wound care outcomes and the dermatology/chronic-wound indications Viromed targets, with similar hospital-channel GTM.
• Smith & Nephew plc: Multinational medical device company with a large Advanced Wound Management franchise alongside orthopedics and sports medicine. Comparable on the dermatology/chronic wound care use cases Viromed targets, including diabetic foot and post-surgical wound healing.
• Coloplast A/S: Danish medical device company with a dedicated Wound & Skin Care business serving hospitals, clinics, and homecare patients. Comparable on chronic wound care indications and patient outcomes focus, though Viromed's cold plasma mechanism is novel versus Coloplast's dressings-based portfolio.
• Drägerwerk AG & Co. KGaA: German-headquartered medical technology company with leading positions in mechanical ventilation, anesthesia, and hospital infection prevention. Highly comparable as a DACH-based medical device maker addressing the same ICU/ventilation and acute-care hospital customers that Viromed sells into with ViroCAP and PulmoPlas.

Broad incumbents

• Steris plc: Global leader in sterilization, disinfection, and infection prevention products across hospitals, pharmaceutical, and life sciences customers. Comparable to Viromed's room air decontamination devices (KLINIK AKUT V 500 Plasma, Virosafe 2500) and overall infection-control mission, though Steris operates at substantially larger scale across a broader portfolio.
• Getinge AB: Swedish medical technology company spanning surgical workflows, intensive care, and sterilization/disinfection. Comparable on ICU infrastructure (where PulmoPlas is targeted) and on hospital hygiene/disinfection (where Viromed's room decontamination line competes).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/viromed

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viromed Medical